MOONLAKE IMMUNOTHERAPEUTICS Debt Instrument, Fair Value Disclosure
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Debt Instrument, Fair Value Disclosure of $32.61 million as of 2022-12-31, per its 10-Q filed 2023-08-10.
Discontinued › Notes
us-gaap:DebtInstrumentFairValue · last filed 2023-08-10
- 2022-12-31: Debt Instrument, Fair Value Disclosure $32.61M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2022-12-31 | $32.61M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |